Biowisdom Extends Collaboration with Astrazeneca

BioWisdom Limited has announced an extension to its existing relationship with AstraZeneca.

The two companies have been working together to build specific Intelligence Networks to enhance AstraZeneca’s drug discovery process.

AstraZeneca will further evaluate BioWisdom’s Sofia™ Platform for the development of Intelligence Networks elsewhere in the business.

"We have been working with BioWisdom for the past two years and have been impressed by the potential of its latest technology development to enhance our scientific understanding of the cause and effects around drug toxicity," said David Cook, Associate Director, Pathways Capability at Astra Zeneca.

"By understanding the effects previous drugs have exhibited on drug toxicity biomarker profiles, in combination with clinical disorders and other factors, we hope to be better able to guide our own discovery and development activities in light of this new knowledge."

"In today’s pharmaceutical R&D environment, being able to support a critical business decision by a systematic assessment of relevant knowledge is a significant competitive advantage."

"By using our Intelligence Networks, AstraZeneca will be in a better position to make more informed decisions based on a coherent picture of all available data," said Gordon Smith Baxter, CEO of BioWisdom.

He added, "The leading pharmaceutical companies increasingly view Intelligence Networks as the new best practice for improved information transparency and decision making, and are coming to BioWisdom. This is a core part of our business and it is growing steadily."

BioWisdom creates Intelligence Networks by codifying knowledge drawn from massively diverse information taken from public, third party and in-house sources.